SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Potential Offer

6 Sep 2010 15:14

RNS Number : 2239S
Silence Therapeutics PLC
06 September 2010
 



 

 

FOR IMMEDIATE RELEASE

 

Potential Offer

 

London, 6 September, 2010 - Silence Therapeutics plc (AIM: SLN) notes the recent share price movement and announces that it has received an approach which may or may not lead to an offer for the Company. A further announcement will be made in due course.

 

For further information, please contact:

 

Silence Therapeutics

Phil Haworth, CEO +1 (650) 855-1514

p.haworth@silence-therapeutics.com

NOMAD

Nomura Code Securities

Richard Potts / Jonathan Senior

+44 20 7776 1200

 

European media and investor enquiries:

M:Communications +44 20 7920 2342

Mary-Jane Elliott / Emma Thompson

 

US media and investor enquiries:

Vida Communication +44 (415) 675-7400

Tim Brons (media)

tbrons@vidacommunication.com 

or

Stephanie Diaz (investors)

sdiaz@vidacommunication.com

 

The City Code on Takeovers and Mergers (the "City Code")

 

1) Rule 2.10 of the City Code

 

In accordance with Rule 2.10 of the City Code, the Company confirms that it has 279,891,452 ordinary shares of 1p each in issue under the ISIN code GB0008433350.

 

2) Disclosure requirements of the Takeover Code (the "Code")

 

Under Rule 8.3(a) of the Code, any person who is interested in 1% or more of any class of relevant securities of an offeree company or of any paper offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the commencement of the offer period and, if later, following the announcement in which any paper offeror is first identified. An Opening Position Disclosure must contain details of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any paper offeror(s). An Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be made by no later than 3.30 pm (London time) on the 10th business day following the commencement of the offer period and, if appropriate, by no later than 3.30 pm (London time) on the 10th business day following the announcement in which any paper offeror is first identified. Relevant persons who deal in the relevant securities of the offeree company or of a paper offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure.

 

Under Rule 8.3(b) of the Code, any person who is, or becomes, interested in 1% or more of any class of relevant securities of the offeree company or of any paper offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any paper offeror. A Dealing Disclosure must contain details of the dealing concerned and of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any paper offeror, save to the extent that these details have previously been disclosed under Rule 8. A Dealing Disclosure by a person to whom Rule 8.3(b) applies must be made by no later than 3.30 pm (London time) on the business day following the date of the relevant dealing.

 

If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a paper offeror, they will be deemed to be a single person for the purpose of Rule 8.3.

 

Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4). Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Takeover Panel's website at www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the offer period commenced and when any offeror was first identified. If you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure, you should contact the Panel's Market Surveillance Unit on +44 (0)20 7638 0129.

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
SPMZQLFBBKFBBBK
Date   Source Headline
30th Mar 20167:00 amRNSHolding(s) in Company
22nd Mar 20167:00 amRNSNotice of Results
18th Jan 20167:00 amRNSBoard changes
12th Nov 20157:00 amRNSBoard appointment
30th Oct 20152:32 pmRNSLicensee's drug to commence Ph 2/Ph 3 trials
29th Sep 20157:00 amRNSInterim Results
22nd Sep 20157:19 amRNSBoard Change and Notice of Results
30th Jul 20157:01 amRNSInterim Board Change
1st Jun 201511:42 amRNSResult of AGM
1st Jun 20157:00 amRNSAGM statement and clinical trial interim analysis
14th May 20159:55 amRNSReplacement: Holding(s) in Company
14th May 20157:00 amRNSClinical trial update
12th May 201510:19 amRNSHolding(s) in Company
11th May 20155:31 pmRNSHolding(s) in Company
11th May 20153:07 pmRNSHolding(s) in Company
11th May 20153:07 pmRNSHolding(s) in Company
11th May 201511:29 amRNSHolding(s) in Company
11th May 201510:50 amRNSHolding(s) in Company
11th May 201510:06 amRNSNotice of AGM
8th May 20155:21 pmRNSHolding(s) in Company
1st May 201510:32 amRNSResult of General Meeting and Additional Listing
16th Apr 20155:48 pmRNSAdditional Listing
8th Apr 201511:33 amRNSFundraising update
2nd Apr 20152:34 pmRNSPreliminary results
2nd Apr 20152:34 pmRNSConditional fundraising of approximately £40m
23rd Mar 20157:00 amRNSClinical trial update
16th Feb 20157:00 amRNSPresentation at RNA Therapeutics conference
12th Feb 20157:00 amRNSSuccessful European patent appeal
27th Jan 20157:00 amRNSGrant of share options
5th Jan 20157:00 amRNSBoard Changes
15th Dec 20147:00 amRNSBoard appointment
1st Dec 20147:00 amRNSTrading update and capital markets presentation
1st Dec 20147:00 amRNSTechnology breakthrough
18th Nov 20147:00 amRNSPublication of study data
3rd Nov 201410:26 amRNSAdditional Listing
22nd Oct 20145:44 pmRNSNotification of Major Interest in Shares
23rd Sep 201411:41 amRNSAdditional Listing
16th Sep 20147:00 amRNSHalf year results
2nd Sep 20149:05 amRNSBoard change
27th Aug 20143:38 pmRNSNotice of Results
5th Aug 20147:00 amRNSPublication of pre-clinical study data
30th Jul 20147:00 amRNSLicensee confirms favourable trial outcome
18th Jul 20144:40 pmRNSSecond Price Monitoring Extn
18th Jul 20144:35 pmRNSPrice Monitoring Extension
17th Jul 20145:01 pmRNSNotification of major interest in shares
16th Jul 20147:00 amRNSCompletion of recruitment for phase 2a trial
9th Jul 20144:40 pmRNSSecond Price Monitoring Extn
9th Jul 20144:35 pmRNSPrice Monitoring Extension
3rd Jul 20144:35 pmRNSPrice Monitoring Extension
27th Jun 20144:16 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.